SCHEDULE: BlackRock Discloses 4.1% Passive Stake in REGENXBIO
Institutional Ownership Disclosure
BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 4.1% passive ownership stake in REGENXBIO INC as of December 31, 2025.
Summary
- BlackRock Portfolio Management LLC, a Delaware-organized entity, reported beneficial ownership of 2,085,619 shares of REGENXBIO INC common stock.
- This aggregate amount represents 4.1% of REGENXBIO INC's outstanding common stock.
- BlackRock Portfolio Management LLC holds sole voting power over 1,818,311 shares and sole dispositive power over all 2,085,619 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing existed.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of REGENXBIO INC.
- Various BlackRock business units, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are involved in the beneficial ownership reporting.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a 13G is a routine disclosure, a significant passive stake by a reputable institutional investor like BlackRock can be seen as a positive signal of confidence in the company, without implying any active engagement or specific strategic moves.
Positives
- A significant passive stake by a major institutional investor like BlackRock can be viewed as a vote of confidence in REGENXBIO INC's long-term prospects.
- The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting stability in the ownership structure.
Negatives
- No specific negative information regarding REGENXBIO INC is disclosed in this ownership filing.
Risks
- The filing itself does not detail specific risks related to REGENXBIO INC's operations or financial health.
- BlackRock's passive intent mitigates the risk of an activist investor seeking to influence company control, at least from this specific holder.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance from REGENXBIO INC or BlackRock regarding the issuer's future performance.
Industry Context
This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive landscape for REGENXBIO INC. However, it confirms continued institutional interest in the biotechnology sector, particularly in companies like REGENXBIO INC.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may provide a degree of confidence in the stock's stability and long-term investment appeal.
- Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this passive ownership filing.
Key Dates
| Date | Description |
|---|---|
| 2025-01-28 | Date of a previously revoked Power of Attorney for BlackRock Portfolio Management LLC. |
| 2025-07-01 | Effective date of the current Power of Attorney for BlackRock Portfolio Management LLC, revoking the prior one. |
| 2025-12-31 | Date of the event which required the filing of this Schedule 13G, reflecting the ownership position. |
| 2026-01-21 | Signature date of the Schedule 13G filing by BlackRock Portfolio Management LLC. |
Keywords
REGENXBIO, BlackRock, Schedule 13G, Institutional Ownership, Common Stock, Biotechnology, Gene Therapy, Investment, Passive Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.